Last reviewed · How we verify
BOTOX® purified neurotoxin complex
Botulinum toxin type A inhibits acetylcholine release at the neuromuscular junction.
Botulinum toxin type A inhibits acetylcholine release at the neuromuscular junction. Used for blepharospasm, strabismus, hemi-facial spasm.
At a glance
| Generic name | BOTOX® purified neurotoxin complex |
|---|---|
| Also known as | Botulinum toxin type A purified neurotoxin complex |
| Sponsor | Allergan |
| Drug class | Neurotoxin |
| Target | Botulinum toxin type A |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
This results in temporary muscle paralysis, which can be used to treat a variety of conditions.
Approved indications
- blepharospasm
- strabismus
- hemi-facial spasm
- cervical dystonia
- axillary hyperhidrosis
Common side effects
- drooping eyelid
- facial asymmetry
- headache
- eye pain
- diplopia
Key clinical trials
- Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor (PHASE2)
- A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines (PHASE4)
- A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants (PHASE3)
- A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence (PHASE3)
- A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence (PHASE3)
- BOTOX® for the Treatment of Platysma Prominence (PHASE2)
- OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17) (PHASE3)
- Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BOTOX® purified neurotoxin complex CI brief — competitive landscape report
- BOTOX® purified neurotoxin complex updates RSS · CI watch RSS
- Allergan portfolio CI